<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="176250">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00801138</url>
  </required_header>
  <id_info>
    <org_study_id>08-647</org_study_id>
    <nct_id>NCT00801138</nct_id>
  </id_info>
  <brief_title>The Effect of Dexamethasone on the Duration of Interscalene Nerve Blocks With Ropivacaine or Bupivacaine</brief_title>
  <official_title>The Effect of Dexamethasone on the Duration of Interscalene Nerve Blocks With Ropivacaine or Bupivacaine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Outcomes Research Consortium</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Outcomes Research Consortium</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will test the hypothesis that the effect of dexamethasone on the analgesic
      duration of interscalene nerve blocks differs between ropivacaine and bupivacaine.
      Participants will be patients undergoing shoulder surgery with an interscalene nerve block.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized study of four groups of patients undergoing shoulder surgery using
      interscalene nerve blocks. The study will investigate the effect of dexamethasone on
      analgesic duration. Participants will be randomized into one of four groups:

        -  Ropivacaine: 30 ml 0.5% ropivacaine plus 2 ml 0.9% saline (placebo) for interscalene
           block;

        -  Bupivacaine: 30 ml 0.5% bupivacaine plus 2 ml 0.9% saline (placebo);

        -  Ropivacaine and steroid: 30 ml 0.5% ropivacaine plus dexamethasone 8 mg (2 ml) mixed
           with the local anesthetic;

        -  Bupivacaine and steroid: 30 ml 0.5% bupivacaine plus dexamethasone 8 mg (2 ml) mixed
           with the local anesthetic.

      The primary outcome is the duration of the interscalene nerve block which is time to first
      administration of pain medication after block

      A blinded observer will interview patients each morning for three days postoperatively,
      either in the hospital or by telephone and at 14 days post operatively.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Based on a strong primary outcome (prolonged analgesia with dexamethasone) and futility for
    type of local anesthetic, study was terminated.
  </why_stopped>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double Blind (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome is the duration of the interscalene nerve block which is time to first administration of pain medication after block</measure>
    <time_frame>Post op days 1,2 and 3 and 14 days after surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>These include time to a significant increase in shoulder discomfort, time to a noticeable decrease in numbness and/or weakness, maximum VRS with rest and movement, and total opioid consumption.</measure>
    <time_frame>Post op days 1,2 and 3 and 14 days after surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">218</enrollment>
  <condition>Shoulder Surgery</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group 1 Ropivacaine: 30 ml 0.5% ropivacaine plus 2 ml 0.9% saline for interscalene block</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group 2 Bupivacaine: 30 ml 0.5% bupivacaine plus 2 ml 0.9% saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group 3 Ropivacaine and dexamethasone:
Ropivacaine plus dexamethasone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group 4 Bupivacaine and steroid:
Bupivacaine plus dexamethasone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine</intervention_name>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine</intervention_name>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>steroid</description>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>saline</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 18 and 75 years

          -  Patients undergoing shoulder procedures such as rotator cuff repair capsular shift
             shoulder arthroplasty subacromial decompression

        Exclusion Criteria:

          -  Contraindications to interscalene block (Coagulopathy, infection at the needle
             insertion site, moderate to severe chronic obstructive pulmonary disease,
             contralateral pneumothorax or diaphragmatic paralysis)

          -  Pregnancy

          -  Preexisting neuropathy involving the surgical limb

          -  Systemic glucocorticoid treatment (for 2 weeks or more) within six months of surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth Cummings, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daniel I Sessler, MD</last_name>
    <role>Study Chair</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ivan Parra Sanchez, MD</last_name>
    <role>Study Director</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2011</verification_date>
  <lastchanged_date>February 17, 2011</lastchanged_date>
  <firstreceived_date>December 2, 2008</firstreceived_date>
  <responsible_party>
    <name_title>Kenneth Cummings, MD</name_title>
    <organization>Cleveland Clinic</organization>
  </responsible_party>
  <keyword>interscalene nerve block</keyword>
  <keyword>analgesia</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
